Compare Bristol-Myers Squibb Co (BMY) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs NICE Ltd — how do they compare? Bristol-Myers Squibb Co trades at $58.36 (market cap $116.30B), while NICE Ltd trades at $104.41 (market cap $6.00B). The key difference: Bristol-Myers Squibb Co is far larger — about 19.4× NICE Ltd's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| BMY | NICE | |
|---|---|---|
Market Cap | $116.30B | $6.00B |
Sector | Health | Technology |
52-Week High | $62.37 | $170.37 |
52-Week Low | $42.60 | $83.15 |
Enterprise Value | $152.24B | $5.78B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
NICE stock trades at $103.48, up 3.75% today, with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with a 65.79% gross margin and consistent earnings beats, including Q1 2026 EPS of $2.64 beating expectations of $2.52. Recent news highlights enterprise AI deployments with Banco do Brasil and Sopra Steria, expanding NICE's global footprint in customer experience solutions.
NICE presents a compelling investment case with attractive valuation (P/E 12.13) and 56.5% analyst buy ratings targeting $124.88 consensus. Key risks include execution challenges in AI integration and competitive pressure from larger tech players. The stock's current proximity to 52-week highs requires monitoring for sustainability of recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
